Sign In
Buy EWTX
$39.73
-1.54 (-3.73%)
At Close: Jul 14, 2026
Servier finalise l'acquisition de l'activité dystrophie musculaire d'Edgewise Therapeutics
08:30am, Monday, 13'th Jul 2026
/PRNewswire/ -- Servier, groupe pharmaceutique international indépendant gouverné par une fondation, a annoncé aujourd'hui avoir finalisé l'acquisition de
— Edgewise receives $1.55 billion in upfront cash and is eligible to receive up to $1.1 billion in regulatory and commercial milestones — — Transaction creates strategically focused cardiovasc
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
08:00am, Wednesday, 01'st Jul 2026
BOULDER, Colo., July 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutic
Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript
06:22am, Wednesday, 17'th Jun 2026
Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript
Edgewise Therapeutics Reports Improvements In Heart Drug Trial
01:40pm, Tuesday, 16'th Jun 2026
Edgewise Therapeutics Inc. (NASDAQ:EWTX) on Tuesday released topline results from the 12-week Part D cohort of its Phase 2 CIRRUS-HCM trial.
Edgewise shares slip after heart-disease drug trial data disappoints investors
11:18am, Tuesday, 16'th Jun 2026
Edgewise Therapeutics shares fell nearly 10% on Tuesday after the efficacy of its experimental heart-disease drug in a mid-stage study fell short of investor expectations.
– No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% – – Consistent and clinically meaningful improvements observed in echocardiogram parameters, biomarker
Edgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement
11:37pm, Thursday, 04'th Jun 2026
Edgewise Therapeutics remains a "Buy," driven by pipeline focus and a transformative $2.65B sale of its muscular dystrophy program to Servier. Company will use the $1.55B upfront cash to fully fund ED
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
04:01pm, Wednesday, 03'rd Jun 2026
BOULDER, Colo., June 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal
12:15pm, Tuesday, 02'nd Jun 2026
EWTX surges 18% to a record high after striking a $2.65 billion neuromuscular business divestiture deal with Servier, sharpening focus on its cardiovascular pipeline.
Edgewise to sell muscle dystrophy business to Servier for up to $2.65 billion
08:34am, Monday, 01'st Jun 2026
Biotech firm Edgewise Therapeutics said on Monday it would sell its experimental muscular dystrophy drug and related business to France's Servier for up to $2.65 billion.
— Edgewise to Receive $1.55 Billion in Upfront Cash Consideration and is Eligible to Receive up to $1.1 Billion in Regulatory and Commercial Milestones — — Transaction Creates Focused Cardiovasc
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026
08:00am, Tuesday, 12'th May 2026
BOULDER, Colo., May 12, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present at th
– Announced positive long-term sevasemten data demonstrating sustained functional stabilization in Becker muscular dystrophy (Becker) up to 3.5 years of follow-up – – CIRRUS-HCM 12-week data
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
08:00am, Monday, 04'th May 2026
BOULDER, Colo., May 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics
